A major phase III trial of capivasertib, a cancer drug discovered following collaborative work between The Institute of Cancer Research, London, and partners, has begun in breast cancer.

A personalised cancer vaccine, used in combination with an immunotherapy drug, triggers a response from the immune system that is specific to the cancer and shows some clinical benefit, according to the results of an early clinical trial presented at the virtual AACR conference.

Cancers are often heavily reliant on breaking down fats for their growth and spread, and could be treated by a highly innovative combination of new drugs and dietary changes, a major new study concludes.